Alector Teams Up With Genentech On Potential Parkinson’s Treatment
Alector, Inc. (NASDAQ:ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it has entered into an exclusive global licensing
Alector joined forces with a big pharma company on Parkinson's research. This shows others believe in their science, which is a good sign.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.